Clinical trial
Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer
NCT00041639 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00041639 |
|---|---|
| Title | Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer |
| Official title | A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Advanced/Metastatic Pancreatic Carcinoma |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Neoplasms |
| Intervention type | Drug |
| Interventions | hMN14 (labetuzumab) |
| Enrollment | 75 |
| Start date | Jan 1, 2000 |
| Completion | Dec 1, 2003 |
| First posted | Jul 15, 2002 |
| Last update posted | Aug 19, 2021 |
| Countries | Germany, Hungary, Netherlands, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: